Year 2018 (52)

Edition nr. 7-8

Adverse cardiovascular effects associated with proton pump inhibitors

  • The study described here provides no definitive answer to the question whether PPIs do indeed cause an elevated cardiac risk.
  • The study shows that there is an increased risk of stroke and myocardial infarction when PPIs are used for more th ...

Read article

Recent research into rivaroxaban

  • Rivaroxaban has clearly found its way into Dutch medical practice, for a limited number of registered indications: for venous thrombo-embolism (treatment and prevention) and for the prevention of thrombus formation in patients with atrial fibri ...

Read article

Proton pump inhibitors for infants

  • Regurgitation by infants and gastro-oesophageal reflux are physiological phenomena and do not require medical treatment. Randomised studies into such medical treatment have found no evidence for its efficacy.
  • According to guidelines for pae ...

Read article

Survival of intensive care patients at elevated risk of delirium

Delirium is a serious condition with an elevated risk of mortality in the short and longer term. This also goes for patients who develop delirium during a stay at an intensive care unit. Hence, preventing delirium is highly clinically relevant, a ...

Read article

Cardiovascular safety of canagliflozin

Adding canagliflozin to an existing therapy in patients with type 2 diabetes and high cardiovascular risk is just as safe as adding a placebo, but may possibly offer only marginally greater cardiovascular protection than placebo.
• Saving one pa ...

Read article